News

MAPLIGHT THERAPEUTICS RECEIVES $8.1 MILLION FOR PARKINSON’S DISEASE RESEARCH

SAN FRANCISCO, CA, November 30, 2020 – MapLight Therapeutics today announced a $8.1 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to undertake a large-scale, systematic investigation of the brain circuits and mechanisms that are responsible for triggering psychiatric symptoms in Parkinson’s disease. Results will inform identification of novel drug targets … Continued

MAPLIGHT THERAPEUTICS ANNOUNCES COMPLETION OF DOSING IN PHASE 1 STUDY OF THERAPY FOR SOCIAL DEFICIT IN AUTISM SPECTRUM DISORDER

Interim data from Phase 1 clinical trial with repeated dosing in healthy volunteers demonstrates positive safety and tolerability profile for ML-004 SAN FRANCISCO, November 23, 2020 – MapLight Therapeutics today announced it has completed dosing of healthy volunteers across five cohorts in a Phase 1 clinical trial evaluating the safety of ML-004, a selective serotonin … Continued